Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD

References

• Gold Reports - Global Initiative for Chronic Obstructive Lung Disease - GOLD. Available from: https://goldcopd.org/gold-reports/. Accessed November 25, 2020.
   Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.00162414
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47. doi:10.2147/copd.2006.1.1.39
   PubMedGoogle Scholar
• Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–913. doi:10.1183/09031936.00146306
   PubMed Web of Science ®Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1646–1652. doi:10.1164/ajrccm.150.6.7952628
   PubMed Web of Science ®Google Scholar
• Keene JD, Jacobson S, Kechris K, et al. Biomarkers predictive of exacerbations in the SPIROMICS and COPD Gene cohorts. Am J Respir Crit Care Med. 2017;195(4):473–481. doi:10.1164/rccm.201607-1330OC
   PubMed Web of Science ®Google Scholar
• Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–2047.e10. doi:10.1016/j.jaci.2018.04.010
   PubMed Web of Science ®Google Scholar
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045–1051. doi:10.2147/COPD.S155306
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790–2798. doi:10.4049/jimmunol.181.4.2790
   PubMed Web of Science ®Google Scholar
• Gorska K, Nejman-Gryz P, Paplinska-Goryca M, Korczynski P, Prochorec-Sobieszek M, Krenke R. Comparative Study of IL-33 and IL-6 levels in different respiratory samples in mild-to-moderate asthma and COPD. COPD. 2018;15(1):36–45. doi:10.1080/15412555.2017.1416074
   PubMedGoogle Scholar
• Jacobsen E, Doyle A, Colbert D, et al. Differential activation of airway eosinophils induces IL-13 mediated allergic Th2 pulmonary responses in mice. Allergy. 2015;70(9):1148–1159. doi:10.1111/all.12655
   PubMed Web of Science ®Google Scholar
• Fanning LB, Boyce JA. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol. 2013;111(3):155–162. doi:10.1016/j.anai.2013.06.031
   PubMed Web of Science ®Google Scholar
• Romano M, Cianci E, Simiele F, Recchiuti A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur J Pharmacol. 2015;760:49–63. doi:10.1016/j.ejphar.2015.03.083
   PubMed Web of Science ®Google Scholar
• Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011;63(3):471–538. doi:10.1124/pr.110.003517
   PubMed Web of Science ®Google Scholar
• Mastalerz L, Celejewska‐Wójcik N, Wójcik K, et al. Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. Clin Exp Allergy. 2015;45(12):1779–1789. doi:10.1111/cea.12654
   PubMed Web of Science ®Google Scholar
• Celejewska‐Wójcik N, Wójcik K, Ignacak‐Popiel M, et al. Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis. Allergy. 2020;75(4):831–840. doi:10.1111/all.14141
   PubMedGoogle Scholar
• Djukanović R, Sterk PJ, Fahy JV, Hargreave§ FE. Standardised methodology of sputum induction and processing. Eur Respir J. 2002;20(37suppl):1s–2s. doi:10.1183/09031936.02.00000102
   PubMed Web of Science ®Google Scholar
• Mastalerz L, Celejewska-Wójcik N, Wójcik K, et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy. 2014;69(11):1550–1559. doi:10.1111/all.12512
   PubMed Web of Science ®Google Scholar
• Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(21):1796–1800. doi:10.1016/j.jchromb.2010.05.012
   PubMed Web of Science ®Google Scholar
• Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koëter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J. 2000;15(1):109–115. doi:10.1183/09031936.00.15110900
   PubMed Web of Science ®Google Scholar
• Weiszhar Z, Horvath I. Induced sputum analysis: step by step. Breathe. 2013;9(4):300–306. doi:10.1183/20734735.042912
   Google Scholar
• Kim VL, Coombs NA, Staples KJ, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017;50(4):1700853. doi:10.1183/13993003.00853-2017
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971. doi:10.1183/09031936.06.00072105
   PubMed Web of Science ®Google Scholar
• Proboszcz M, Mycroft K, Paplinska-Goryca M, et al. Relationship between blood and induced sputum eosinophils, bronchial hyperresponsiveness and reversibility of airway obstruction in mild-to-moderate Chronic Obstructive Pulmonary Disease. COPD. 2019;16(5–6):354–361. doi:10.1080/15412555.2019.1675150
   PubMedGoogle Scholar
• Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495–1504. doi:10.2147/COPD.S100338
   PubMed Web of Science ®Google Scholar
• Zahraei HN, Guissard F, Paulus V, Henket M, Donneau A-F, Louis R. Comprehensive Cluster analysis for COPD including systemic and airway inflammatory markers. J Chronic Obstr Pulm Dis. 2020;17(6):672–683. doi:10.1080/15412555.2020.1833853
   PubMed Web of Science ®Google Scholar
• Górska K, Paplińska-Goryca M, Nejman-Gryz P, Goryca K, Krenke R. Eosinophilic and neutrophilic airway inflammation in the phenotyping of mild-to-moderate asthma and chronic obstructive pulmonary disease. COPD. 2017;14(2):181–189. doi:10.1080/15412555.2016.1260539
   PubMedGoogle Scholar
• Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol. 2015;135(3):822–824.e2. doi:10.1016/j.jaci.2014.09.034
   PubMed Web of Science ®Google Scholar
• Hartjes FJ, Vonk JM, Faiz A, et al. Predictive value of eosinophils and neutrophils on clinical effects of ICS in COPD. Respirol Carlton Vic. 2018;23(11):1023–1031. doi:10.1111/resp.13312
   PubMed Web of Science ®Google Scholar
• Mycroft K, Krenke R, Górska K. Eosinophils in COPD—Current concepts and clinical implications. J Allergy Clin Immunol Pract. 2020;8(8):2565–2574. doi:10.1016/j.jaip.2020.03.017
   PubMed Web of Science ®Google Scholar
• White AA, Doherty TA. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis. Am J Rhinol Allergy. 2018;32(1):7–11. doi:10.2500/ajra.2018.32.4498
   PubMed Web of Science ®Google Scholar
• Sanak M, Gielicz A, Bochenek G, Kaszuba M, Niżankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol. 2011;127(5):1141–1147.e2. doi:10.1016/j.jaci.2010.12.1108
   PubMed Web of Science ®Google Scholar
• Levy BD, Bonnans C, Silverman ES, et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med. 2005;172(7):824–830. doi:10.1164/rccm.200410-1413OC
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Moodley YP, Thompson PJ, Misso NL. Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation. Clin Exp Allergy. 2010;40(1):85–93. doi:10.1111/j.1365-2222.2009.03386.x
   PubMed Web of Science ®Google Scholar
• Huynh M-LN, Malcolm KC, Kotaru C, et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med. 2005;172(8):972–979. doi:10.1164/rccm.200501-035OC
   PubMed Web of Science ®Google Scholar
• Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245–252. doi:10.1016/j.jaci.2014.07.031
   PubMed Web of Science ®Google Scholar
• Chou K-T, Su K-C, Hsiao Y-H, et al. Post-bronchodilator reversibility of FEV1 and eosinophilic airway inflammation in COPD. Arch Bronconeumol. 2017;53(10):547–553. doi:10.1016/j.arbr.2017.01.027
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, De-torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5):1701162. doi:10.1183/13993003.01162-2017
   PubMed Web of Science ®Google Scholar
• Cai C, Bian X, Xue M, et al. Eicosanoids metabolized through LOX distinguish asthma–COPD overlap from COPD by metabolomics study. Int J Chron Obstruct Pulmon Dis. 2019;14:1769–1778. doi:10.2147/COPD.S207023
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. doi:10.1183/13993003.01446-2016
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Gao J, Iwamoto H, Koskela J, et al. Characterization of sputum biomarkers for asthma–COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2457–2465. doi:10.2147/COPD.S113484
   PubMed Web of Science ®Google Scholar
• Inoue H, Nagase T, Morita S, Yoshida A, Jinnai T, Ichinose M. Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach. Int J Chron Obstruct Pulmon Dis. 2017;12:1803–1810. doi:10.2147/COPD.S133859
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283–289. doi:10.2147/COPD.S30651
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Yamanda S, Ishida M, Yanai M. Inflammatory biomarkers in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2117–2123. doi:10.2147/COPD.S113647
   PubMed Web of Science ®Google Scholar
• GINA Main Report - Global Initiative for Asthma - GINA. Available from: https://ginasthma.org/gina-reports/. Accessed November 25, 2020.
   Google Scholar
• Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48(9):331–337. doi:10.1016/j.arbres.2011.12.009
   PubMed Web of Science ®Google Scholar
• Rhee CK. Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome. Korean J Intern Med. 2015;30(4):443–449. doi:10.3904/kjim.2015.30.4.443
   PubMed Web of Science ®Google Scholar